Identifying microRNA markers for heart transplant rejection and complications
Official title: MicroRNA Biomarkers of Allograft Rejection and Cardiac Allograft Vasculopathy in Cardiac Transplantation
Funded at Inova Health Care Services · NIH-10869894 · Data updated 2026-11-12
This study is looking at tiny molecules in your blood that could help doctors spot heart transplant issues early, making it easier to keep you healthy after your surgery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Inova Health Care Services NIH-funded |
| Lab location | 1 site (Fairfax, UNITED STATES) |
| Project start | July 1, 2020 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $184,680 |
| NIH project number | 5K23HL143179-05 |
| Project ID | NIH-10869894 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have undergone heart transplantation and are at risk for allograft rejection or cardiac allograft vasculopathy.
✕Less likely to help
Patients who have not received a heart transplant or those with other unrelated cardiovascular conditions may not benefit from this research.
What this research studies
This research focuses on exploring circulating, cell-free microRNAs (ccf-miRs) as potential non-invasive biomarkers for detecting allograft rejection and cardiac allograft vasculopathy (CAV) in heart transplant patients. The approach involves isolating these microRNAs from blood samples and using advanced genomic sequencing techniques to analyze them. By combining transcriptomic data with clinical information, the research aims to develop a clinical panel of biomarkers that can help in the early detection of transplant complications, ultimately improving patient management and outcomes.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate detection of heart transplant rejection, potentially saving lives and improving the quality of care for transplant recipients.
How similar studies have gone: Previous research has shown promise in using biomarkers for transplant rejection, indicating that this approach could be a meaningful advancement in the field.
Where this research is happening
-
Inova Health Care Services
Fairfax, United States Active
Researchers
- Principal investigator: Shah, Palak — Inova Health Care Services
- Study coordinator: Shah, Palak
Related research
Other NIH-funded projects on the same topics.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
Immunological mechanisms behind treatment-resistant kidney transplant rejection
This grant explores why certain kidney transplant rejections don’t respond to standard treatments and what immune cells in the graft are driving that resistance.
-
Targeting graft T cells to reduce transplant rejection
A patient-facing study exploring how immune cells within transplanted organs drive rejection and how we might reduce trouble for people who need organ transplants.
-
Engineered kidney 'chip' to study antibody-driven rejection and how the body adapts
A kidney-rejection research grant is developing a miniaturized, human cell–based chip to model how antibodies cause rejection and how kidneys may adapt.
-
Social media, mood, and teens: how the menstrual cycle affects rejection feelings and online experiences
Teenagers using social media may feel stronger negative reactions to online feedback, especially around certain times in their menstrual cycle, which could relate to mood and depression.
-
Understanding how BK virus links infection to kidney transplant rejection
This project looks at how BK polyomavirus reactivation affects kidney transplant patients and aims to use pre-transplant T cell information to tailor immunosuppression and monitoring.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.